The FDA granted fast-track designation to VBL Therapeutics' VB-111, its drug candidate for recurrent glioblastoma multiforme. The gene therapy, designed to be given as a simple IV infusion, was previously awarded orphan status in the U.S. and Europe. VB-111 is also under development for treatment of differentiated thyroid cancer and ovarian cancer.

Full Story:
Globes (Israel)

Related Summaries